FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents

Regeneron Contacts:

Media Relations

Sharon Chen

Tel: +1 (914) 847-1546

[email protected]

Investor Relations

Mark Hudson

Tel: +1 (914) 847-3482 

[email protected] 

Sanofi Contacts:

Media Relations

Ashleigh Koss

Tel: +1 (908) 981-8745

[email protected]

Investor Relations

George Grofik

Tel: +33 (0)1 53 77 45 45

[email protected]